Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6827151 | 0.78 | KDM4E (0.58) | TSHRTDP1ALOX5MAPTKMT2A | |
| SCHEMBL6561975 | 0.74 | ALOX5 (0.70) | ALOX5CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6562061 | 0.72 | L3MBTL1 (0.61) | TSHRTDP1ALOX5MAPTKMT2A | |
| SCHEMBL6565677 | 0.72 | ALOX5 (0.45) | TDP1ALOX5CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6565474 | 0.71 | ALOX5 (0.53) | ALOX5CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20271984 | 0.71 | SMN1; SMN2 (0.69) | USP2TSHRMAPTKMT2AMEN1 | |
| SCHEMBL6563451 | 0.70 | ALOX5 (0.52) | ALOX5CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6563445 | 0.70 | ALOX5 (0.52) | ALOX5CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6565776 | 0.70 | L3MBTL1 (0.70) | TDP1ALOX5CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11840409 | 0.69 | ALOX5 (0.59) | TSHRALOX5CYP3A4MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399426-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING BETA-AMYLOID PRODUCTION | Active Pass Pharmaceuticals, Inc. (CA) | 2004-03-24 | — | — | EP | disclosed |
| US-20030191144-A1 | Compounds, compositions and methods for modulating beta-amyloid production | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2003-10-09 | — | — | US | disclosed |
| US-20030125338-A1 | Compounds, compositions and methods for modulating beta-amyloid production | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2003-07-03 | — | — | US | disclosed |
| WO-2002100836-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING BETA-AMYLOID PRODUCTION | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2002-12-19 | — | — | WO | disclosed |
| US-3940394-A | ANTILIPEMIC | SANTILLI ARTHUR A | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125338-A1 | Compounds, compositions and methods for modulating beta-amyloid production | APP, PPARA, PPARG | USP2 3289/4885TSHR 3453/4885TDP1 1731/4885 |
| US-20030191144-A1 | Compounds, compositions and methods for modulating beta-amyloid production | APP, PPARA, PPARG | USP2 3289/4885TSHR 3453/4885TDP1 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.